Persistence Pays Off For Amicus: Positive Migalastat Data In Hand

Amicus will return to FDA with positive data on its oral small molecule chaperone migalastat in Fabry patients after a Phase III trial showed the oral drug had comparable efficacy to existing enzyme replacement therapies.